Historical Archive

Pfizer launches joint venture in China with Hisun

The joint venture is for the development, manufacturing and marketing of generic drugs in China and world markets with an investment of US$295 million

Pfizer has entered into a joint venture with Chinese pharmaceutical company Zhejiang Hisun Pharmaceuticals to develop, manufacture and commercialize generic drugs in China and worldwide markets with an investment of $295 million. Hisun-Pfizer Pharmaceuticals has a registered capital of $250 million, with Hisun controlling 51% and Pfizer controlling 49%. The off-patent medicines sector is a rapidly growing segment, especially in emerging markets, Pfizer said in a statement. The US pharmaceutical company estimated that in China, own-brand generics account for 70% of the domestic pharmaceutical market. "The joint venture is a milestone in Pfizer's commitment to China's healthcare reforms and expanding the reach of its products in China," said Xiaobing Wu, Pfizer country manager for China.

13 September 2012 – Milan Finance


Articoli correlati

Back to top button
Fedaiisf Federazione delle Associazioni Italiane degli Informatori Scientifici del Farmaco e del Parafarmaco